2 weeks Ago
O2O CREATIVE/E+ via Getty Images Investment Overview AbCellera ( NASDAQ: ABCL ) completed its IPO in December 2020, raising ~$483m, at $20 per share. In its IPO press release, the company called itself "a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research.
I hope to see you there. Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies.
He leads the investing group Haggerston BioHealth . Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.
I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.
No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body..
